Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Menu Search
The Sidney Kimmel Comprehensive Cancer Center

In This Section      

Our Team

Mary Armanios, M.D

Professor of Oncology, Genetic Medicine, Pathology, and Molecular Biology and Genetics
Director, Telomere Center at Johns Hopkins
Associate Director, Sidney Kimmel Comprehensive Cancer Center 
for Cancer Research Training and Education

Dr. Armanios is a physician-scientist whose clinical and research interests have been focused on understanding the role of telomere biology in cancer and age-related disease. Her group has defined the spectrum of the telomere syndromes, coining their name and defining their underlying genetic basis and molecular mechanisms. Dr. Armanios discovered a role for telomere dysfunction in the susceptibility to pulmonary fibrosis among other conditions and has defined the clinical settings where recognition of telomere-mediated disease impacts patient care. Dr. Armanios follows one of the largest cohorts of patients with inherited mutations in telomerase and telomere-related genes in the world. She co-founded and now directs the Telomere Center at Johns Hopkins which includes basic and clinical research operations. The Telomere Center clinical efforts have included a long-standing Telomere Clinic which is supported by a muti-disciplinary team of experts who care for patients with bone marrow failure, pulmonary and liver disease as well as cancer. Dr. Armanios and her colleagues have founded and she has overseen the operations of the Johns Hopkins Telomere Lab; a unique diagnostic facility that serves patients and clinicians from around the world.

Robert Brodsky, M.D.

Director, Division of Hematology
Professor of Medicine and Oncology

Dr. Brodsky's clinical research involves the study of aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), and other bone marrow failure disorders. His work has demonstrated that high doses of the drug cyclophosphamide, without bone marrow transplantation, can lead to durable complete remissions in severe aplastic anemia. He and his colleagues in neurology and rheumatology are applying this approach in other severe autoimmune disorders such as scleroderma, myasthenia gravis, multiple sclerosis and autoimmune hematologic disorders. Dr. Brodsky's major laboratory interests relate to the study of normal and abnormal blood cell development, including studies of PIG-A gene mutations in aplastic anemia. His group has developed a novel diagnostic assay for PNH based on the pore-forming toxin aeromonas hydrophila.

Amy DeZern, M.D.

Assistant Professor of Medicine and Oncology

Dr. DeZern is a clinical investigator with a focused interest in diagnosing and treating undifferentiated bone marrow failure disorders. In addition to maintaining an active research program, she sees patients with acute leukemia and all types of bone marrow failure. She has particular experience and expertise in the diagnosis and management of aplastic anemia, myelodysplastic syndrome and acute leukemia, and immune-mediated cytopenias.

Richard Jones, M.D.

Director, Bone Marrow Transplant Program
Co-Director, Hematologic Malignancies Program
Professor of Oncology and Medicine

Malignancies Program; professor of oncology and medicine
Research is to better understand the biology of normal and abnormal blood cell development, with an eye to improving the treatment of blood disorders by translating promising findings to the clinic. A primary area of focus is the identification and biologic characterization of cancer stem cells.

Michael McDevitt, M.D.

Assistant Professor of Medicine and Oncology

Dr. McDevitt specializes in the class evaluation of anemias, thrombocytopenias, and other hematology disorders. His research interests include the identification and characterization of tumor suppressor genes on chromosome 7 that contribute to the development of bone marrow cancers.

B. Douglas Smith, M.D.

Associate Professor of Oncology

Dr. Smith's research focuses on taking new, promising laboratory insights and developing them into biology-based treatment approaches for patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS).

Collaborators in the Division of Hematology, Johns Hopkins School of Medicine:

Allison Moliterno, M.D.

Associate Professor of Medicine

Dr. Moliterno's clinical research involves the study of chronic myeloproliferative disorders including polycythemia vera, essential thrombocytosis and idiopathic myelofibrosis. Her research focuses on genetic and epigenetic lesions associated with MPDs with the goal of improving diagnosis and treatment for these disorders.

Jerry Spivak, M.D.

Director, Center for the Chronic Myeloproliferative Disorders
Professor of Medicine and Oncology

Dr. Spivak's research interests focused on chronic myeloproliferative disorders with particular emphasis on the molecular basis of these disorders and the means for distinguishing them both diagnostically and with respect to therapeutic intervention. Using techniques to analyze gene expression in polycythemia vera stem cells, he has found that polycythemia vera patients can be distinguished from patients with erythrocytosis and also divided into two groups: those with aggressive disease versus less aggressive. He and his colleagues also are studying the role of specific molecular markers identified at Johns Hopkins and elsewhere related to the development and diagnosis of polycythemia vera.

Collaborator in Pediatrics, Johns Hopkins School of Medicine:

Heather Symons, M.D., MHS

Associate Professor of Oncology

Dr. Symons, a pediatric oncologist, has several research interests in addition to caring for patients. One project focuses on using a novel immunotherapy approach to treating both solid tumors and hematologic (blood-borne) malignancies. Evaluating an experimental therapy, Dr. Symons is pairing donor lymphocytes (white blood cells that activate the body's immune system) with chemotherapy to determine if this combination will jumpstart patients' immune systems attack cancer cells. In another project, she is examining ways to reduce bone marrow transplant-related complications ordinarily associated with some donors after high-dose chemotherapy.

Advanced Practice Providers

Viki Anders, CRNP

Nicky Hughes Hallett, PA-C

Jackie Jung, CRNP

Kiryoung Kim, CRNP

Ana Lazarevic, CRNP

Brandon Raab, CRNP

Audra Shedeck, CRNP

Jose Jeffrey (Jay) C. Topico, MSN, CRNP

Amber Zukas, CRNP